A new study points to shorter treatments for prostate cancer as experts notice the patients of shorter treatments to be enjoying the similar length of life as is lived to by the men, who are treated for longer periods. Then why are the men being given longer treatments?

In the results of their study, the experts have clearly stated that men, who have high-risk prostate cancer and are receiving the treatment through 18 months hormone therapy have been noticed to be living just as long as the ones, who are treated for a more standard 36 months treatment.

Applying the above study results in practice would imply that men should be given much shorter treatment for their cancers because it will also help them spare from months of unpleasant side effects, suggested the researchers on Tuesday.

"This may well change the standard of care," said Dr. Bruce J. Roth, a prostate cancer specialist at Washington University in St. Louis. "Three years of hormonal therapy was almost picked randomly, and there's nothing magical about that duration," he added.

A news conference for the Genitourinary Cancers Symposium has also been scheduled on starting Thursday in Orlando, Fla., and the above results will be presented at the event.